Recreation use of phosphodiesterase type 5 inhibitors, the other side of erectile dysfunction

Giovanni Maria Fusco; Luigi Cirillo; Francesco Mastrangelo; Francesco Romano; Ernesto Di Mauro; Gianluigi Cacace; Gianluca Spena; Annamaria Iannicelli; Corrado Aniello Franzese; Vincenzo Mirone; Roberto La Rocca; Luigi Napolitano

doi:10.4081/aiua.2023.11350

Recreation use of phosphodiesterase type 5 inhibitors, the other side of erectile dysfunction

Arch Ital Urol Androl. 2023 May 29;95(2):11350. doi: 10.4081/aiua.2023.11350.

Affiliations

¹ Department of Neurosciences, Reproductive Sciences and Odontostomatology, Urology Unit, University of Naples "Federico II", Naples. [email protected].
² Department of Neurosciences, Reproductive Sciences and Odontostomatology, Urology Unit, University of Naples "Federico II", Naples. [email protected].
³ Department of Neurosciences, Reproductive Sciences and Odontostomatology, Urology Unit, University of Naples "Federico II", Naples. [email protected].
⁴ Department of Neurosciences, Reproductive Sciences and Odontostomatology, Urology Unit, University of Naples "Federico II", Naples. [email protected].
⁵ Department of Neurosciences, Reproductive Sciences and Odontostomatology, Urology Unit, University of Naples "Federico II", Naples. [email protected].
⁶ Department of Neurosciences, Reproductive Sciences and Odontostomatology, Urology Unit, University of Naples "Federico II", Naples. [email protected].
⁷ Department of Neurosciences, Reproductive Sciences and Odontostomatology, Urology Unit, University of Naples "Federico II", Naples. [email protected].
⁸ Department of Translational Medical Sciences, University of Naples "Federico II", Naples. [email protected].
⁹ ASL Napoli 3 Sud, Naples. [email protected].
¹⁰ Department of Neurosciences, Reproductive Sciences and Odontostomatology, Urology Unit, University of Naples "Federico II", Naples. [email protected].
¹¹ Department of Neurosciences, Reproductive Sciences and Odontostomatology, Urology Unit, University of Naples "Federico II", Naples. [email protected].
¹² Department of Neurosciences, Reproductive Sciences and Odontostomatology, Urology Unit, University of Naples "Federico II", Naples. [email protected].

PMID: 37254932
DOI: 10.4081/aiua.2023.11350

Abstract

To the Editor, In 1998 Sildenafil was approved by the Food and Drug Administration as first line therapy for erectile dysfunction. Since then, phosphodiesterase type 5 inhibitors (PDE5i) represent the first-line treatment of erectile dysfunction (ED), improving physiological erectile function, sexual orgasmic function, psychological self-esteem, couples' relationship, and quality of life. [...].

MeSH terms

Erectile Dysfunction* / drug therapy
Erectile Dysfunction* / psychology
Humans
Male
Phosphodiesterase 5 Inhibitors* / therapeutic use
Quality of Life
Sildenafil Citrate* / therapeutic use

Substances

Phosphodiesterase 5 Inhibitors
Sildenafil Citrate